Investors & Media

FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS

Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) Approval based on reduction of neurofilament, a biomarker associated with neuronal damage in ALS QALSODY joins SPINRAZA ® as Ionis-discovered medicine approved for

Read more
You are now leaving to visit